Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2003

View Archived Issues

New glucose-lowering agents covered by BMS patent

Merck KGaA presents new agents able to inhibit PDE4 and TNF-alpha production

New factor Xa and/or factor VIIa inhibitors under study at Merck KGaA

Rigel researchers present novel anti-HCV agents

Agents for iron overload therapy disclosed by Novartis researchers

Enanta develops new macrolides

Novel antiangiogenic combretastatin analogues with utility in cancer therapy

Celsion treats first patient in Thermodox trial for prostate cancer

Milnacipran has distinct mechanisms for effects on pain and mood

Prefilled Avonex syringe approved

Lescol and Lescol XL approved for new indication

Corixa and GSK enter Bexxar agreement for Canada

Asimadoline reduces pain threshold associated with colon distension in IBS

Improved hemodynamics reported with sitaxsentan in pulmonary hypertension

SR-140333B effective and well tolerated in ulcerative colitis

Good efficacy and cardiovascular safety profile reported for cilomilast in COPD

Pregabalin improves anxiety scores and work productivity in GAD

Inflazyme acquisition of GlycoDesign approved

Amgen and Tularik form oncology collaboration

Allos updates operating plan for 2003

Cardiome plans phase III for RSD-1235

Pharma Mar advances kahalalide F into phase II for liver carcinoma

Levaquin approved for treatment of chronic bacterial prostatitis

Orally active, small-molecule CXCR3 antagonist represents a new class of transplant therapeutics

NC-1153: a novel immunosuppressant that selectively targets Jak3

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...